BioPharma Mexico is where experts like Shire Mexico meet to network, learn from each other, and discuss the latest developments in biopharma.

What Does Shire Mexico Have to Say About Orphan Drugs?

We’re excited to announce that Raul Vivar, General Director of Shire Mexico, will be speaking at this year’s BioPharma Mexico. Raul’s presentation is titled “Accessing public institutions: A success story changing the lives of lysosomal disease patients”, and will take place at 4:05 pm on Wednesday, November 5th. Don’t miss it! Download our interview with Raul here During his presentation, …

BioPharma Mexico is where experts like Shire Mexico meet to network, learn from each other, and discuss the latest developments in biopharma.

¿Qué Dice Shire Sobre los Medicamentos Huérfanos en México?

Es un placer contar con la participacion de Raúl Vivar, Director General de Shire México, como uno de nuestros ponentes en BioPharma México 2014. Raúl hablará sobre El acceso a instituciones de salud públicas: Una historia de éxito cambiando la vida de pacientes con enfermedades lisosomales, el miércoles, 5 de noviembre a las 16.05 de la tarde. ¡No te lo …

Obama, Shire, Abbvie

Days After AbbVie-Shire Deal, Obama Slams Tax Inverters

AbbVie recently announced intentions to acquire Shire Pharmaceuticals, and shifting their HQ to Ireland. Obama had some strong words about the practice, known as “Tax Inversion.” When a company acquires another that has business in Ireland, it is possible for that company to shift their HQ from the United States to their newly acquired assets across the Atlantic. This comes …

eBook: Top 10 Orphan Drug Pipelines in Europe

Who has the most robust and promising pipeline of orphan medicinal products in Europe? This is the question we asked ourselves as we brought together the speaking faculty and constructed the programme for the 4th Annual World Orphan Drug Congress in Geneva. As the orphan drug market grows at an enviable rate, the pharmaceutical industry have shifted focus and investments …

Download Press Release: Shire Announces the Establishment of Shire Japan KK

Tokyo, Japan- April 8 2013- Shire officially announces the establishment of Shire Japan KK. The new Shire Japan KK office is located in the Kita-Shinjuku area of Tokyo and is represented by Vice President and Representative Director, Steve Engen. The establishment of Shire Japan KK underscores the company’s commitment to patients in Japan. “We are very pleased to be strengthening …

Download Press Release: Shire to Acquire SARcode Bioscience, Expands Presence in Ohthalmology

Lexington, MA, US- March 25, 2013- Shire today announced that it will acquire SARcode Bioscience Inc., a privately held biopharmaceutical company based in Brisbane, California. The acquisition continues to build Shire’s presence in the ophthalmology therapeutic category and brings a new phase 3 compound- LIFITEGRAST- currently under development for the signs and symptoms of dry eye disease, into Shire’s portfolio. …

Download Press Release: Shire Acquires Premacure AB

Lexington, MA, US- March 12, 2013- Shire announces that it has acquired Premacure AB of Uppsala, Sweden, a privately held biotechnology company developing a protein replacement therapy, currently in Phase II development, for the prevention of retinopathy of prematurity (ROP). ROP is a rare and potentially blinding eye disorder that primarily affects premature infants and is one of the most …

Download Press Release: Shire Supports Rare Disease Day 2013

On February 28 2013, at Lexington, Massachusetts, US, Shire announced its support of Rare Disease Day, joining patients, healthcare providers, and patient organisations around the world to support a day that focuses attention on rare diseases as a public health issue, and highlights the need for more understanding and awareness about these diseases. Observed annually on the last day of …

Download Press Release: Shire Acquires Lotus Tissue Repair, Inc

Lexington, MA, US- January 8, 2013- Shire announces that it has signed an agreement to acquire Lotus Tissue Repair, Inc. of Cambridge, MA, a privately held biotechnology company developing the first and only protein replacement therapy currently being investigated for the treatment of dystrophic epidermolysis bullosa (DEB). DEB is a devastating orpahn disease for which no currently approved treatment option …

Download Shire’s Rare Disease Impact Report: Insights from patients and the medical community

In January 2013, Shire put together a Rare Disease Import Report, after a four-week period of online surveys conducted among US/ UK rare disease patients and their caregivers, physicians who treat patients with rare diseases, payors handling reimbursements for healthcare plans and governments/institutions, and thought leaders in the rare disease space. These surveys conducted, were fielded through market research agency …